Cargando…

ODP339 Nonfunctioning Giant Adenomas

INTRODUCTION: Giant pituitary tumors (GA), those with 4 cm or more on the largest axis, exhibit extension beyond the sella turcica and invade structures adjacent to it. OBJECTIVES: To evaluate demographic, clinical, and imaging variables in a cohort of nonfunctioning GA(NGA) patients. METHODS: We co...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliveira, Miriam C, Nesello, Alberto C, Pereira-Lima, Ana Paula S, Rech, Carolina GSL, Pereira-Lima, Julia Fernanda S, Corso, Eduardo Raul B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625201/
http://dx.doi.org/10.1210/jendso/bvac150.1048
_version_ 1784822430347296768
author Oliveira, Miriam C
Nesello, Alberto C
Pereira-Lima, Ana Paula S
Rech, Carolina GSL
Pereira-Lima, Julia Fernanda S
Corso, Eduardo Raul B
author_facet Oliveira, Miriam C
Nesello, Alberto C
Pereira-Lima, Ana Paula S
Rech, Carolina GSL
Pereira-Lima, Julia Fernanda S
Corso, Eduardo Raul B
author_sort Oliveira, Miriam C
collection PubMed
description INTRODUCTION: Giant pituitary tumors (GA), those with 4 cm or more on the largest axis, exhibit extension beyond the sella turcica and invade structures adjacent to it. OBJECTIVES: To evaluate demographic, clinical, and imaging variables in a cohort of nonfunctioning GA(NGA) patients. METHODS: We conducted a retrospective and observational study of patients with NGA followed in our tertiary center between 2005 and 2021. We evaluated variables related to diagnosis, treatment, and follow-up. RESULTS: We found 48 patients diagnosed with NGA. Most patients were men (n=35, 73%), and meanage at diagnosis 55.5 ± 11.8 years (35-83). Symptoms such as headache and visual alteration were present within 13 years of diagnosis. The BMI was higher than 30 in 10 cases, two with morbid obesity. Among the comorbidities, 10 patients had diabetes mellitus and one glucose intolerance; hypertension was present in 20 cases and depression in 7. Polymedication was verified in 20 patients. Pituitary MRI revealed the largest tumor axis between 4-4.9 cm in 33 patients, 5-5.9 cm in 9, and equal or greater than 6 cm in 6. In 14 cases, there was intraventricular extension, invasion of the sphenoid sinus in 11, cavernous sinus in 21, frontal lobe in 1, temporal region in 6, clivus in 3, retroclivus in 3, and rhinopharynx in one. Hyperprolactinemia was detected in 17 cases (maximum value: 70.8 ng/mL). Only three patients presented all hormonal axes intact. Respectively, 9, 15, 11, and 8 patients presented 1, 2, 3, or 4 deficient axes. Hypocortisolism was present in 18 cases, GH deficiency in 16, hypothyroidism in 32, hypogonadism in 35, and hypoprolactinemia in 3. Four patients had diabetes insipidus. Ten cases of the 44 who underwent surgery underwent two interventions and 4 cases, 3. Nine patients underwent radiotherapy. After the first surgery, 26 patients had follow-up greater than 12 months (13 to 214 months). The last image showed a giant lesion in 7 cases, macroadenoma with a larger axis less than 4 cm in 15 cases, a lesion restricted to the sella in 3 cases, and 1 case without lesion. CONCLUSION: In our cohort, the results show the handling difficulty of NGA, determined by the complex removal of the lesion, high degree of invasion to adjacent structures, and tumor regrowth. Sequential therapeutic decisions in this group of patients require a qualified multidisciplinary team to maximize the patients’ life expectancy and quality of life while working on sharing experiences and investing in the tumor molecular characterization and new molecules that add to the poor therapeutic arsenal available. Presentation: No date and time listed
format Online
Article
Text
id pubmed-9625201
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-96252012022-11-14 ODP339 Nonfunctioning Giant Adenomas Oliveira, Miriam C Nesello, Alberto C Pereira-Lima, Ana Paula S Rech, Carolina GSL Pereira-Lima, Julia Fernanda S Corso, Eduardo Raul B J Endocr Soc Neuroendocrinology and Pituitary INTRODUCTION: Giant pituitary tumors (GA), those with 4 cm or more on the largest axis, exhibit extension beyond the sella turcica and invade structures adjacent to it. OBJECTIVES: To evaluate demographic, clinical, and imaging variables in a cohort of nonfunctioning GA(NGA) patients. METHODS: We conducted a retrospective and observational study of patients with NGA followed in our tertiary center between 2005 and 2021. We evaluated variables related to diagnosis, treatment, and follow-up. RESULTS: We found 48 patients diagnosed with NGA. Most patients were men (n=35, 73%), and meanage at diagnosis 55.5 ± 11.8 years (35-83). Symptoms such as headache and visual alteration were present within 13 years of diagnosis. The BMI was higher than 30 in 10 cases, two with morbid obesity. Among the comorbidities, 10 patients had diabetes mellitus and one glucose intolerance; hypertension was present in 20 cases and depression in 7. Polymedication was verified in 20 patients. Pituitary MRI revealed the largest tumor axis between 4-4.9 cm in 33 patients, 5-5.9 cm in 9, and equal or greater than 6 cm in 6. In 14 cases, there was intraventricular extension, invasion of the sphenoid sinus in 11, cavernous sinus in 21, frontal lobe in 1, temporal region in 6, clivus in 3, retroclivus in 3, and rhinopharynx in one. Hyperprolactinemia was detected in 17 cases (maximum value: 70.8 ng/mL). Only three patients presented all hormonal axes intact. Respectively, 9, 15, 11, and 8 patients presented 1, 2, 3, or 4 deficient axes. Hypocortisolism was present in 18 cases, GH deficiency in 16, hypothyroidism in 32, hypogonadism in 35, and hypoprolactinemia in 3. Four patients had diabetes insipidus. Ten cases of the 44 who underwent surgery underwent two interventions and 4 cases, 3. Nine patients underwent radiotherapy. After the first surgery, 26 patients had follow-up greater than 12 months (13 to 214 months). The last image showed a giant lesion in 7 cases, macroadenoma with a larger axis less than 4 cm in 15 cases, a lesion restricted to the sella in 3 cases, and 1 case without lesion. CONCLUSION: In our cohort, the results show the handling difficulty of NGA, determined by the complex removal of the lesion, high degree of invasion to adjacent structures, and tumor regrowth. Sequential therapeutic decisions in this group of patients require a qualified multidisciplinary team to maximize the patients’ life expectancy and quality of life while working on sharing experiences and investing in the tumor molecular characterization and new molecules that add to the poor therapeutic arsenal available. Presentation: No date and time listed Oxford University Press 2022-11-01 /pmc/articles/PMC9625201/ http://dx.doi.org/10.1210/jendso/bvac150.1048 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Neuroendocrinology and Pituitary
Oliveira, Miriam C
Nesello, Alberto C
Pereira-Lima, Ana Paula S
Rech, Carolina GSL
Pereira-Lima, Julia Fernanda S
Corso, Eduardo Raul B
ODP339 Nonfunctioning Giant Adenomas
title ODP339 Nonfunctioning Giant Adenomas
title_full ODP339 Nonfunctioning Giant Adenomas
title_fullStr ODP339 Nonfunctioning Giant Adenomas
title_full_unstemmed ODP339 Nonfunctioning Giant Adenomas
title_short ODP339 Nonfunctioning Giant Adenomas
title_sort odp339 nonfunctioning giant adenomas
topic Neuroendocrinology and Pituitary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625201/
http://dx.doi.org/10.1210/jendso/bvac150.1048
work_keys_str_mv AT oliveiramiriamc odp339nonfunctioninggiantadenomas
AT neselloalbertoc odp339nonfunctioninggiantadenomas
AT pereiralimaanapaulas odp339nonfunctioninggiantadenomas
AT rechcarolinagsl odp339nonfunctioninggiantadenomas
AT pereiralimajuliafernandas odp339nonfunctioninggiantadenomas
AT corsoeduardoraulb odp339nonfunctioninggiantadenomas